
This rare, chronic autoimmune disease can cause kidney failure if left untreated

Teva will get US commercialisation rights for Eticovo upon close and infliximab in Q3 2027

The agreement gives Fresenius exclusive option rights for up to 37 potential first-to-market biosimilar candidates

The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care

If approved, this treatment would offer a new option for the nearly one million Americans living with MS

The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases

MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain

The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company

This is the first treatment breakthrough in pulmonary fibrosis in over a decade

This is the first and only at-home subcutaneous treatment option for this disease

The collaboration began in 2013 and was later expanded in 2020 and 2023

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years